Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis.

Show simplified metadata
dc.contributor.authorWang, Jie
dc.contributor.authorChen, Hongyu
dc.contributor.authorTang, Zihuan
dc.contributor.authorZhang, Jinquan
dc.contributor.authorXu, Yuanwei
dc.contributor.authorWan, Ke
dc.contributor.authorHussain, Kifah
dc.contributor.authorGkoutos, Georgios V
dc.contributor.authorHan, Yuchi
dc.contributor.authorChen, Yucheng
dc.contributor.departmentTranslational Medicineen_US
dc.contributor.roleAdditional Professional Scientific and Technical Fielden_US
dc.contributor.trustauthorGeorgios, Gkoutos, V
dc.date.accessioned2023-10-17T14:03:07Z
dc.date.available2023-10-17T14:03:07Z
dc.date.issued2023-08-24
dc.description.abstractFifteen studies comprising 2765 patients (mean age 75.9 ± 9.3 years; 83.7% male) with a mean follow-up duration of 18.7 ± 17.1 months were included in the meta-analysis. There was a decrease in left ventricular ejection fraction (LVEF) (standard mean differences (SMD: -0.17; 95% confidence interval (CI), -0.31 to -0.03; P = 0.02) but were no significant differences in intraventricular septum (IVS) thickness or global longitudinal strain (GLS) after tafamidis treatment. However, subgroup analysis showed no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment (SMD: -0.11; 95% CI, -0.34 to 0.12, P = 0.34). In addition, the group with tafamidis treatment had a decreased risk for all-cause death or heart transplantation compared to patients without treatment (the pooled RR, 0.44; 95% CI, 0.31-0.65; P < 0.01). Subgroup analysis showed that there was no significant difference of tafamidis on the outcomes in patients with wild-type or hereditary ATTR (RR, 0.44; 95% CI, 0.27-0.73 versus 0.21, 95% CI, 0.11-0.40, P = 0.08). Furthermore, tafamidis treatment was associated with a lower risk of the composite endpoint (RR, 0.57; 95% CI, 0.42-0.77; P < 0.01).en_US
dc.identifier.citationWang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, Hussain K, Gkoutos GV, Han Y, Chen Y. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine. 2023 Aug 24;63:102172. doi: 10.1016/j.eclinm.2023.102172. PMID: 37662524; PMCID: PMC10474377.en_US
dc.identifier.doi10.1016/j.eclinm.2023.102172
dc.identifier.eissn2589-5370
dc.identifier.pmid37662524
dc.identifier.urihttp://hdl.handle.net/20.500.14200/2584
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.urlhttps://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00349-8/fulltexten_US
dc.rights© 2023 The Author(s).
dc.source.beginpage102172
dc.source.countryEngland
dc.source.endpage
dc.source.journaltitleEClinicalMedicine
dc.source.volume63
dc.subjectCardiologyen_US
dc.subjectHealth services. Managementen_US
dc.titleTafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis.en_US
dc.typeArticle
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
UHB Cardiology